Skip to main content
Publications
Pineda E, Salud A, Vila-Navarro E, Safont MJ, Llorente B, Aparicio J, Vera R, Escudero P, Casado E, Bosch C, Bohn U, Perez-Carrion R, Carmona A, Ayuso JR, Ripolles T, Bouzas R, Gironella M, Garcia-Albeniz X, Feliu J, Maurel J. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial. Tumour Biol. 2017 Jun;39(6). doi: 10.1177/1010428317705509
Afonso A, Schmiedl S, Becker C, Tcherny-Lessenot S, Primatesta P, Plana E, Souverein P, Wang Y, Korevaar JC, Hasford J, Reynolds R, de Groot MC, Schlienger R, Klungel O, Rottenkolber M. A methodological comparison of two European primary care databases and replication in a US claims database: inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction. Eur J Clin Pharmacol. 2016 Sep;72(9):1105-16.
Gulmez SE, Larrey D, Pageaux GP, Lignot-Maleyran S, de Vries C, Sturkenboom M, Perez-Gutthann S, Benichou J, Bissoli F, Horsmans Y, Bernuau J, Stricker B, Thorburn D, Blin P, Moore N. Methodology for a multinational case–population study on liver toxicity risks with NSAIDs: the Study of Acute Liver Transplant (SALT). Eur J Clin Pharmacol. 2013 Mar 1;69(3):605-16.
Domingo-Domenech J, Castel T, Auge JM, Garcia-Albeniz XA, Conill C, Puig S, Vilella R, Matas J, Malvehy J, Gascon P, Mellado B, Molina R. Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients. Tumour Biol. 2007;28(5):264-82.
Sakamoto C, Sugano K, Ota S, Sakaki N, Takahashi S, Yoshida Y, Tsukui T, Osawa H, Sakurai Y, Yoshino J, Mizokami Y, Mine T, Arakawa T, Kuwayama H, Saigenji K, Yakabi K, Chiba T, Shimosegawa T, Sheehan JE, Perez-Gutthann S, Yamaguchi T, Kaufman DW, Sato T, Kubota K, Terano A. Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol. 2006;62(9):765-72.